Innoprot assay development platform combinens both target-based and phenotypic screening due to their important role to move from in-vitro to in-vivo pharmacology for a high range of disease pathways. It can be directed toward the best detection technology for a given molecular target and screening objective.
Innoprot offers in vitro models for many diseases, including Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Laterial Sclerosis or Ischemic Stroke. These models mimick known pathways associated to each disease, allowing the screening of compounds of these diseases directly using of fluorescent microscopy analysis.
Showing all 9 results